Ultime notizie per Cingulate (NASDAQ:CING) Azioni

Cingulate

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Cingulate Inc

COINSILIUM GROUP LTD ORD by Coinsilium Group Ltd.

Coinsilium Group Ltd

WIIM

Telephone and Data Systems shares are trading lower after the company reported worse-than-expected Q3 financial results and lowered its FY24 US cellular service revenue guidance.

Guggenheim analyst Yatin Suneja maintains argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Buy and raises the price target from $585 to $665.

News

Price Target

Analyst Ratings

ARGX

Guggenheim Maintains Buy on argenx, Raises Price Target to $665

VIAV

Viavi Solutions shares are trading higher after Rosenblatt raised its price target on the stock from $8.25 to $10.5 and Northland Capital Markets raised its price target from $11 to $13.

Guggenheim maintains Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) with a Buy and raises the price target from $45 to $52.

KYMR

Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $52

CVCO

Cavo Industries shares are trading higher after the company reported better-than-expected Q2 financial results and announced a $100 million stock repurchase program.

<a href="https://www.bloomberg.com/news/articles/2024-11-01/meta-loses-bid-to-appeal-uk-class-action-over-user-data">https://www.bloomberg.com/news/articles/2024-11-01/meta-loses-bid-to-appeal-uk-class-action-over-user-data</a>
<a href="https://www.bloomberg.com/quote/FB:US">Meta Platforms Inc.</a> failed in a bid to challenge a class action suit in the UK that alleged Facebook abused its dominant position and exploited its users personal data.
The <a href="https://www.bloomberg.com/quote/6152Z:LN">UK</a>'s Court of Appeal refused to permit Meta and Facebook's UK unit to challenge a competition appeals court which had greenlit a revised version of the lawsuit. The court rejected Meta's appeal at a hearing on October 7, but only published the detailed ruling on Friday.

Legal

'Meta Loses Bid To Appeal UK Class Action Over User Data' - Bloomberg News

Guggenheim analyst Shahriar Pourreza maintains Entergy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>) with a Buy and raises the price target from $145 to $165.

Guggenheim Maintains Buy on Entergy, Raises Price Target to $165

PATK

Patrick Industries shares are trading lower after the company reported worse-than-expected Q3 financial results. Also, Raymond James lowered its price target on the stock from $160 to $138.

Guggenheim analyst Robert Drbul maintains Kontoor Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KTB#NYSE">KTB</a>) with a Buy and raises the price target from $80 to $100.

Guggenheim Maintains Buy on Kontoor Brands, Raises Price Target to $100

VRRM

Verra Mobility shares are trading lower after the company reported worse-than-expected Q3 revenue results and issued FY24 revenue guidance below estimates. Also, Barid and Deutsche Bank lowered their respective price targets on the stock.

ONTO

Onto Innovation shares are trading lower after Needham cut its price target on the stock from $245 to $230.

Microsoft Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) decision to shut down Arkane Austin, the studio behind acclaimed titles like Redfall and Prey, has faced blunt criticism from industry veteran and Arkane founder Raphaël Colantonio. 
Colantonio, now leading WolfEye Studios, described the decision <a href="https://www.pcgamer.com/games/microsoft-closing-arkane-austin-was-a-dumb-move-says-founder-and-former-president/">to</a> PC Gamer as "stupid" and "not a good decision."
<h3 class="wp-block-heading">A &#8216;Special Group&#8217; Cut In A Corporate Reshuffle</h3>
Reflecting on the closure, Colantonio said: "I think if you look a little bit, it&#8217;s obvious that Arkane Austin was a very special group of people that have made some cool things and that could pull it off again." 
See Also: <a href="https://www.benzinga.com/general/gaming/24/06/39417676/microsoft-issues-redfall-hero-pass-dlc-refunds-after-arkane-austin-closure">Microsoft Issues Redfall Hero Pass DLC Refunds After Arkane Austin Closure</a>
He added: "I think it was a decision that just came down to, &#8216;We need to cut something.&#8217; Was it to please the investors, the stock market? They&#8217;re playing a different game."
The closure of Arkane Austin, alongside studios like Tango Gameworks and Alpha Dog Games, formed part of a broader reorganization within Microsoft, which had announced plans to reduce its gaming division workforce by 1,900 employees. 
In a memo, Xbox Game Studios head Matt Booty cited "reprioritization of titles and resources" as the driving force behind the cuts. 
While Microsoft&#8217;s CEO Satya Nadella received a notable pay raise to $30 million last year, the company continues to grapple with evolving industry demands and cost pressures.
<h3 class="wp-block-heading">Irreplaceable Talent And The Challenge Of Rebuilding</h3>
Colantonio doubted whether the unique chemistry at Arkane Austin could ever be replicated. He pointed to key team members like Harvey Smith and Ricardo Bare, whose collaboration played a huge role in the studio&#8217;s achievements. 
"When you have that magic of Harvey and Ricardo etc. that all come together, it&#8217;s a specific moment in time and space that just worked out this way, that took forever to reach,&#8221; he said. &#8220;Those people together can really make magic."
"It's not like, &#8216;Doesn&#8217;t matter, we&#8217;ll just rehire.&#8217; No, try it. That's what big groups do all the time. They try to just hire massively and overpay people to create those magic groups. It doesn't work like this. So to me, that was stupid. But what do I know?"
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/06/39534876/bethesda-game-studios-montreal-announces-unionization-plans">Bethesda Game Studios Montreal Announces Unionization Plans</a></li>
</ul>
Image credits: Shutterstock.

Gaming

General

MSFT

Microsoft's Decision To Shut Down Arkane Austin Called 'Stupid' By Studio Founder

MDGL

Madrigal Pharmaceuticals shares are trading higher after UBS maintained a Buy rating on the stock and raised its price target from $411 to $441.

MDU Resources shares are trading lower. Everus Construction Group completed its spinoff from the company.

Benchmark analyst Josh Sullivan maintains FTAI Aviation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) with a Buy and raises the price target from $150 to $300.

FTAI

Benchmark Maintains Buy on FTAI Aviation, Raises Price Target to $300

ARES

Ares Management shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Bio-Rad Laboratories shares are trading higher after Citigroup maintained a Buy rating on the stock and raised its price target from $400 to $450.

Church & Dwight shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 net sales guidance.

<ul>
<li>IMPACT-TD Registry, the largest study evaluating holistic effects of tardive dyskinesia (TD), highlights that there is a high burden of TD on quality of life regardless of a person's underlying mental health condition</li>
<li>Registry revealed fewer patients with psychotic disorders (36%) received TD diagnoses compared to those with mood disorders (50%)</li>
<li>Teva continues to further innovations in mental health and progress real-world data to improve treatment optimization</li>
</ul>
TEL AVIV, Israel and PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, revealing differences between TD patients with a psychotic disorder and those with a mood disorder. The IMPACT-TD Registry is the largest study of its kind evaluating the holistic effects of TD, showing real-world treatment patterns and outcomes with once-daily AUSTEDO&#xAE; XR&#xAE; (deutetrabenazine) extended-release tablets and twice-daily AUSTEDO (deutetrabenazine) tablets. Teva also announced interim data from a patient-reported survey describing early, real-world experience with AUSTEDO XR. These findings are being presented at the Psych Congress 2024 taking place from October 29 – November 2 in Boston, MA.

Biotech

TEVA

Teva Presents New Tardive Dyskinesia Data At Psych Congress 2024 From The IMPACT-TD Registry, Revealing Differences In Patient Experience Based On Underlying Psychiatric Condition; Registry Revealed Fewer Patients With Psychotic Disorders (36%) Received TD Diagnoses Compared To Those With Mood Disorders (50%)

MBLY

Mobileye Global shares are trading higher after Baird and TD Cowen raised their respective price targets on the stock.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cingulate Inc (CING – Research Report), Indaptus Therapeutics (IN...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cingulate Inc (CING), Indaptus Therapeutics (INDP) and Immunocore Holdings (IMCR)

Cingulate Inc (CING) has shared an update. Stockholders at Cingulate Inc.'s 2024 Annual Meeting voted in favor of key proposals that impact the com...

Cingulate Inc. Stockholders Bolster Governance and Growth Strategy

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic on Thursday and we have breakdowns of all the latest news sending shares higher and lower this morning!



Moving stocks this morning are share sales, a new order, a closed public offering and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Blue Star Foods (NASDAQ:<a href="https://investorplace.com/stock-quotes/bsfc-stock-quote/">BSFC</a>) stock is rocketing more than 67% alongside heavy pre-market trading.</li>



<li>Volcon (NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/">VLCN</a>) shares are surging over 67% after UBS Group AG (NYSE:<a href="https://investorplace.com/stock-quotes/ubs-stock-quote/">UBS</a>) <a href="https://www.benzinga.com/news/24/07/39725326/ev-maker-volcons-stock-skyrockets-over-70-in-pre-market-following-ubs-groups-buy-sell-transactions">bought and sold shares</a>.</li>



<li>CNS Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cnsp-stock-quote/">CNSP</a>) stock is soaring more than 51% alongside strong early morning trading.</li>



<li>MingZhu Logistics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ygmz-stock-quote/">YGMZ</a>) shares are gaining over 42% with strong pre-market trading today.</li>



<li>Actelis Networks (NASDAQ:<a href="https://investorplace.com/stock-quotes/asns-stock-quote/">ASNS</a>) stock is heading more than 30% higher on a <a href="https://www.nasdaq.com/press-release/actelis-receives-260000-order-major-mid-atlantic-us-county-traffic-system">traffic system order</a>.</li>



<li>Phoenix Motor (NASDAQ:<a href="https://investorplace.com/stock-quotes/pev-stock-quote/">PEV</a>) shares are increasing over 18% despite a lack of news this morning.</li>



<li>Kazia Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) stock is climbing more than 17% as it <a href="https://investorplace.com/2024/07/why-is-kazia-therapeutics-kzia-stock-up-300-today/">continues a recent rally</a>.</li>



<li>Salarius Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/slrx-stock-quote/">SLRX</a>) shares are rising close to 16% with heavy early morning trading.</li>



<li>Staffing 360 Solutions (NASDAQ:<a href="https://investorplace.com/stock-quotes/staf-stock-quote/">STAF</a>) stock is jumping over 13% on Thursday without any clear news.</li>



<li>Naas Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/naas-stock-quote/">NAAS</a>) shares are up 13% as part of an ongoing rally.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>TuanChe (NASDAQ:<a href="https://investorplace.com/stock-quotes/tc-stock-quote/">TC</a>) stock is plummeting more than 33% without any apparent news this morning.</li>



<li>Warrantee (NASDAQ:<a href="https://investorplace.com/stock-quotes/wrnt-stock-quote/">WRNT</a>) shares are diving over 27% on Thursday.</li>



<li>Inspire Veterinary (NASDAQ:<a href="https://investorplace.com/stock-quotes/ivp-stock-quote/">IVP</a>) stock is tumbling more than 26% after <a href="https://www.nasdaq.com/press-release/inspire-veterinary-partners-announces-closing-6-million-public-offering-2024-07-10">closing a public offering</a>.</li>



<li>Quhuo (NASDAQ:<a href="https://investorplace.com/stock-quotes/qh-stock-quote/">QH</a>) shares are taking an over 19% beating after a recent rally.</li>



<li>Cingulate (NASDAQ:<a href="https://investorplace.com/stock-quotes/cing-stock-quote/">CING</a>) stock is sliding more than 18% following a surprise rally yesterday.</li>



<li>Next Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxtt-stock-quote/">NXTT</a>) shares are dropping over 16% on Thursday morning.</li>



<li>Janover (NASDAQ:<a href="https://investorplace.com/stock-quotes/jnvr-stock-quote/">JNVR</a>) stock is decreasing more than 15% <a href="https://www.nasdaq.com/press-release/janovers-new-insurtech-platform-launches-do-liability-insurance-publicly-traded">after climbing higher yesterday</a>.</li>



<li>Zapp Electric Vehicles (NASDAQ:<a href="https://investorplace.com/stock-quotes/zapp-stock-quote/">ZAPP</a>) shares are slipping over 14% as it <a href="https://investorplace.com/2024/07/why-is-zapp-electric-vehicles-zapp-stock-down-25-today/">continues to retreat</a>.</li>



<li>Telesis Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/tbio-stock-quote/">TBIO</a>) stock is dipping nearly 14% after a similar rise yesterday.</li>



<li>SAI.TECH Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/sai-stock-quote/">SAI</a>) shares close out our pre-market stock movers down more than 13% <a href="https://www.nasdaq.com/press-release/saitech-announces-mou-signings-heatnuc-targeting-nuclear-and-smr-markets-middle-east">following a rally yesterday</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-july-11th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Cingulate files for 6.6M common stock offering

Cingulate GAAP EPS of -$5.47

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cingulate (NASDAQ:<a href="https://investorplace.com/stock-quotes/cing-stock-quote/">CING</a>) just reported results for the second quarter of 2024.<ul><li>Cingulate reported earnings per share of -$5.47. This was below the analyst estimate for EPS of -47 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/cing-stock-earnings-cingulate-for-q2-of-2024/">CING Stock Earnings: Cingulate Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CING Stock Earnings: Cingulate Misses EPS for Q2 2024

In a report released yesterday, Naz Rahman from Maxim Group maintained a Hold rating on Cingulate Inc (CING – Research Report). The company's share...

Maxim Group Sticks to Their Hold Rating for Cingulate Inc (CING)

Cingulate files to sell 1M shares of common stock for holders

An announcement from Cingulate Inc ( ($CING) ) is now available. Cingulate Inc. has reinstated the pre-cut salaries of its top executives and conti...

Cingulate Inc: Executive Pay Restored, Funding Up, FDA Study Launched

Cingulate files to sell 1.5M shares of common stock for holders

ASNS

BSFC

CING

CNSP

IMCR

INDP

JNVR

KZIA

NAAS

NXTT

SLRX

STAF

TBIO

VLCN

WRNT

YGMZ

ZAPP

Screenshot 2024-09-03 at 6.27.41 PM

Interview

New ADHD Medication Is On Track For NDA Filing Within A Year – Hear From This Biotech&#39;s CEO

Screenshot 2024-07-02 at 9.57.07 AM

This Biotech Just Cleared A Big FDA Hurdle In Its Quest To Improve ADHD Treatment

Screenshot 2024-06-17 at 5.44.16 PM

Cingulate (NASDAQ: CING) Receives FDA Clearance To Apply For New ADHD Drug Approval

Screenshot 2024-05-07 at 10.50.27 PM

FDA New Drug Application In The Works For This Innovator In ADHD Drug Delivery

Press Releases

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Financing

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Earnings

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Comments

Cingulate

Notizie

Ultime notizie per Cingulate (NASDAQ:CING) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO